Ectoine-Containing Inhalation Solution versus Saline Inhalation Solution in the Treatment of Acute Bronchitis and Acute Respiratory Infections: A Prospective, Controlled, Observational Study.
Acute Disease
/ therapy
Administration, Inhalation
Adolescent
Adult
Aged
Aged, 80 and over
Amino Acids, Diamino
/ administration & dosage
Bronchitis
/ drug therapy
Child
Child, Preschool
Female
Humans
Male
Middle Aged
Respiratory Tract Infections
/ drug therapy
Saline Solution
/ administration & dosage
Young Adult
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
11
2018
accepted:
10
01
2019
entrez:
6
3
2019
pubmed:
6
3
2019
medline:
14
6
2019
Statut:
epublish
Résumé
This study investigated an inhalation solution containing ectoine, a bacterial-derived extremolyte, for the treatment of acute bronchitis and acute respiratory infections in comparison with saline inhalation solution. This prospective, controlled, observational study comprised an inclusion visit (day 1), a final visit (day 7), and a follow-up questionnaire (day 17). The treatment itself was administered from day 1 to day 7. The Bronchitis Severity Score, patients' general health, general effectiveness of the treatment, tolerability, and adverse events were compared between two groups. In total, 135 patients were recruited; 79 patients received ectoine inhalation solution and 56 saline inhalation solution. After treatment, symptom scores decreased significantly in both groups ( Ectoine inhalation solution seems to be slightly more effective than saline inhalation solution for the treatment of acute bronchitis and acute respiratory infections.
Identifiants
pubmed: 30834276
doi: 10.1155/2019/7945091
pmc: PMC6374829
doi:
Substances chimiques
Amino Acids, Diamino
0
Saline Solution
0
ectoine
7GXZ3858RY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7945091Références
Explore (NY). 2005 Nov;1(6):437-45
pubmed: 16781588
Appl Microbiol Biotechnol. 2006 Oct;72(4):623-34
pubmed: 16957893
Arzneimittelforschung. 2006;56(9):652-60
pubmed: 17063641
Curr Med Res Opin. 2007 Feb;23(2):323-31
pubmed: 17288687
Skin Pharmacol Physiol. 2007;20(4):211-8
pubmed: 17519560
Arzneimittelforschung. 2007;57(9):607-15
pubmed: 17966760
Appl Environ Microbiol. 2008 Dec;74(23):7286-96
pubmed: 18849444
Am J Respir Crit Care Med. 2009 Jul 1;180(1):29-35
pubmed: 19324973
Curr Med Res Opin. 2010 Jun;26(6):1413-22
pubmed: 20387996
Pathobiology. 2013;80(2):102-10
pubmed: 23108005
Part Fibre Toxicol. 2012 Dec 10;9:48
pubmed: 23228165
Curr Med Res Opin. 2013 Jul;29(7):739-46
pubmed: 23621514
Skin Pharmacol Physiol. 2014;27(2):57-65
pubmed: 23949258
J Allergy (Cairo). 2014;2014:708458
pubmed: 24822073
J Allergy (Cairo). 2014;2014:176597
pubmed: 24982680
Pneumologie. 2014 Aug;68(8):542-6
pubmed: 25003904
Part Fibre Toxicol. 2015 Jul 04;12:20
pubmed: 26141115
Int J Mol Sci. 2016 Jan 15;17(1):null
pubmed: 26784183
Extremophiles. 2016 May;20(3):251-9
pubmed: 27071404
Sci Rep. 2016 Aug 16;6:31434
pubmed: 27527336
Int J Chron Obstruct Pulmon Dis. 2016 Oct 18;11:2573-2583
pubmed: 27799756